FIGURE 3.

m⁶A modification level of FAM111A‐DT was increased and correlated with poor survival in hepatocellular carcinoma (HCC). (A–C) N6‐methyladenosine (m⁶A) modification levels of 501 site (A), 779 site (B), and 881 site (C) on FAM111A‐DT in immortalized liver cell lines THLE‐2 and THLE‐3, and HCC cell lines SK‐HEP‐1, HuH‐7, Hep3B, and SNU‐398 were measured by SELECT. Results are shown as mean ± SD of n = 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant, by one‐way ANOVA followed by Dunnett's multiple comparisons test. (D–F) m⁶A modification levels of 501 site (D), 779 site (E), and 881 site (F) on FAM111A‐DT in 82 pairs of HCC tissues and adjacent noncancerous liver tissues were measured by SELECT. Results are shown as median with interquartile range. p < 0.0001 by Wilcoxon matched‐pairs signed‐rank test. (G–I) Kaplan–Meier survival analysis of the correlation between m⁶A modification levels of 501 site (G), 779 site (H), or 881 site (I) on FAM111A‐DT and overall survival in our HCC cohort containing 82 cases. p and HR values were calculated by log‐rank test.